New treatment for chronic kidney disease using a special peptide
Novel Therapeutic for Kidney Failure: A Modified, Water-Soluble Orally-Active Caveolin-1 Scaffolding Domain Peptide with Improved Characteristics for Drug Development
This study is exploring a new pill that could help people with chronic kidney disease by improving kidney function and reducing damage, and it's designed to find out how safe and effective this treatment can be.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Fibrotherapeutics, INC. NIH-funded |
| Lab location | 1 site (Charleston, United States) |
| Project ID | NIH-11005463 on NIH RePORTER |
What this research studies
This research focuses on developing a new oral treatment for chronic kidney disease (CKD) using a modified peptide derived from caveolin-1, which has shown promise in reducing fibrosis and improving kidney function in preclinical models. The researchers aim to enhance the peptide's properties to make it more effective and suitable for drug development. By testing the peptide's efficacy in various models, they hope to establish a treatment that can reverse kidney damage and improve patient outcomes. The study will involve assessing the safety and effectiveness of this new compound in a controlled setting.
Who could benefit from this research
Good fit: Ideal candidates for this research are adults aged 21 and older who are suffering from chronic kidney disease or related conditions.
Not a fit: Patients with acute kidney injury or those who do not have chronic kidney disease may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide a novel oral treatment option that significantly improves kidney function and quality of life for patients with chronic kidney disease.
How similar studies have performed: Previous research has shown promising results with similar peptide-based therapies in other fibrotic diseases, indicating potential for success in this novel approach.
Where this research is happening
Charleston, United States
- Fibrotherapeutics, INC. — Charleston, United States (Active)
Researchers
- Principal investigator: Hoffman, Stanley R — Fibrotherapeutics, INC.
- Study coordinator: Hoffman, Stanley R
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.